| Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases K Bloom, A Ely, C Mussolino, T Cathomen, P Arbuthnot Molecular Therapy 21 (10), 1889-1897, 2013 | 256 | 2013 |
| Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs S Carmona, A Ely, C Crowther, N Moolla, FH Salazar, PL Marion, N Ferry, ... Molecular Therapy 13 (2), 411-421, 2006 | 154 | 2006 |
| Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo A Ely, T Naidoo, S Mufamadi, C Crowther, P Arbuthnot Molecular Therapy 16 (6), 1105-1112, 2008 | 122 | 2008 |
| Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA MS Weinberg, A Ely, S Barichievy, C Crowther, S Mufamadi, S Carmona, ... Molecular Therapy 15 (3), 534-541, 2007 | 117 | 2007 |
| Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles A Ely, T Naidoo, P Arbuthnot Nucleic acids research 37 (13), e91-e91, 2009 | 91 | 2009 |
| Gene therapy for chronic HBV—can we eliminate cccDNA? K Bloom, MB Maepa, A Ely, P Arbuthnot Genes 9 (4), 207, 2018 | 80 | 2018 |
| Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus B Moyo, K Bloom, T Scott, A Ely, P Arbuthnot Virus research 244, 311-320, 2018 | 76 | 2018 |
| ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells T Scott, B Moyo, S Nicholson, MB Maepa, K Watashi, A Ely, MS Weinberg, ... Scientific reports 7 (1), 7401, 2017 | 66 | 2017 |
| Advances with RNAi-based therapy for hepatitis B virus infection F van Den Berg, SW Limani, N Mnyandu, MB Maepa, A Ely, P Arbuthnot Viruses 12 (8), 851, 2020 | 57 | 2020 |
| Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors C Crowther, A Ely, J Hornby, S Mufamadi, F Salazar, P Marion, ... Human gene therapy 19 (11), 1325-1332, 2008 | 55 | 2008 |
| Progress and prospects of anti-HBV gene therapy development MB Maepa, I Roelofse, A Ely, P Arbuthnot International Journal of Molecular Sciences 16 (8), 17589-17610, 2015 | 52 | 2015 |
| Exploiting the RNA interference pathway to counter hepatitis B virus replication P Arbuthnot, S Carmona, A Ely Liver International 25 (1), 9-15, 2005 | 49 | 2005 |
| Countering hepatitis B virus infection using RNAi: how far are we from the clinic? D Ivacik, A Ely, P Arbuthnot Reviews in medical virology 21 (6), 383-396, 2011 | 41 | 2011 |
| Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs J Hean, C Crowther, A Ely, R ul Islam, S Barichievy, K Bloom, ... Artificial DNA: PNA & XNA 1 (1), 17-26, 2010 | 41 | 2010 |
| Progress with developing use of gene editing to cure chronic infection with hepatitis B virus A Ely, B Moyo, P Arbuthnot Molecular therapy 24 (4), 671-677, 2016 | 40 | 2016 |
| Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter MB Mowa, C Crowther, A Ely, P Arbuthnot BioMed research international 2014, 2014 | 34 | 2014 |
| AAV-mediated expression of broadly neutralizing and vaccine-like antibodies targeting the HIV-1 envelope V2 region FT van den Berg, NA Makoah, SA Ali, TA Scott, RE Mapengo, ... Molecular Therapy Methods & Clinical Development 14, 100-112, 2019 | 31 | 2019 |
| Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses D Ivacik, A Ely, N Ferry, P Arbuthnot Gene therapy 22 (2), 163-171, 2015 | 31 | 2015 |
| Sustained inhibition of HBV replication in vivo after systemic injection of AAVs encoding artificial antiviral primary microRNAs MB Maepa, A Ely, W Grayson, P Arbuthnot Molecular Therapy-Nucleic Acids 7, 190-199, 2017 | 25 | 2017 |
| Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus T Dreyer, S Nicholson, A Ely, P Arbuthnot, K Bloom Biochemical and biophysical research communications 478 (4), 1563-1568, 2016 | 25 | 2016 |
